These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 18221300)

  • 21. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
    Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.
    Seto WK; Liu K; Fung J; Wong DK; Yuen JC; Hung IF; Lai CL; Yuen MF
    Antivir Ther; 2012; 17(7):1255-62. PubMed ID: 22951420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
    Li Y; Zhang Y; Wang JP; Lian JQ; Bai XF
    J Viral Hepat; 2013 Apr; 20 Suppl 1():46-51. PubMed ID: 23458524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.
    Lee YS; Chung YH; Kim JA; Kim SE; Shin JW; Kim KM; Lim YS; Park NH; Lee HC; Lee YS; Suh DJ
    Liver Int; 2009 Apr; 29(4):552-6. PubMed ID: 19323782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
    Zhao H; Zhang YX; Chen XY; Wang L; Tang XP; Si CW
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):294-7. PubMed ID: 17637268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virologic response and resistance to adefovir in patients with chronic hepatitis B.
    Fung SK; Chae HB; Fontana RJ; Conjeevaram H; Marrero J; Oberhelman K; Hussain M; Lok AS
    J Hepatol; 2006 Feb; 44(2):283-90. PubMed ID: 16338024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
    Lampertico P; Viganò M; Manenti E; Iavarone M; Lunghi G; Colombo M
    Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Rapti I; Dimou E; Mitsoula P; Hadziyannis SJ
    Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B].
    Kim IH; Kim SH; Kim HC; Shin KD; Kim SW; Lee SO; Lee ST; Kim DG
    Korean J Hepatol; 2007 Sep; 13(3):349-62. PubMed ID: 17898551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
    Kang SH; Yim HJ; Kim HR; Kang K; Suh SJ; Lee HJ; Yoon EL; Kim JH; Seo YS; Yeon JE; Byun KS
    J Clin Gastroenterol; 2014; 48(10):889-95. PubMed ID: 24440937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir.
    Lee JM; Kim HJ; Park JY; Lee CK; Kim DY; Kim JK; Lee HW; Paik YH; Lee KS; Han KH; Chon CY; Hong SP; Nguyen T; Ahn SH
    Antivir Ther; 2009; 14(5):705-12. PubMed ID: 19704174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
    Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Du Jeong I; Bang SJ; Park NH
    Antivir Ther; 2012; 17(2):387-94. PubMed ID: 22293395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
    Lee YS; Suh DJ; Lim YS; Jung SW; Kim KM; Lee HC; Chung YH; Lee YS; Yoo W; Kim SO
    Hepatology; 2006 Jun; 43(6):1385-91. PubMed ID: 16729316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B.
    Scotto G; Palumbo E; Fazio V; Tartaglia A; Saracino A; Angarano G
    New Microbiol; 2005 Jul; 28(3):193-7. PubMed ID: 16240690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
    Lee JH; Yoon JH; Cho EJ; Yang HJ; Jang ES; Kwak MS; Hwang SY; Yu SJ; Lee CH; Kim YJ; Kim CY; Lee HS
    J Clin Gastroenterol; 2012 Mar; 46(3):243-50. PubMed ID: 21716122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of therapy in patients with chronic hepatitis B virus.
    Arrese E; Basaras M; Blanco S; Ruiz P; Cisterna R
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):736-40. PubMed ID: 19550344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
    Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.